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Abstract 
Hypertension is emerging in many developing nations as a leading cause of cardiovascular 
mortality, morbidity and disability in adults. In sub-Saharan Africa (SSA) countries it has 
specificities like occurring in young and active adults, resulting in severe complications 
dominated by heart failure and taking place in limited resource settings where individual 
access to treatment (affordability) is very limited.  
Within this context of restrained economic conditions, the greatest gains for SSA in 
controlling the hypertension epidemic lie in its prevention. Attempts should be made to early 
detect hypertensive patients before irreversible organ damage becomes apparent, and to 
provide them with the best possible and affordable non-pharmacological and pharmacological 
treatment. Therefore, efforts should be made in detection and early management at the 
community level.  
In this context, a standardized algorithm of management can help in rational use of available 
resources. Although many international and regional guidelines have been published, they 
cannot apply to SSA settings, because countries economy and patients’ affordability do not 
allow access to advocated treatment. In addition, none of them suggest a clear algorithm of 
management for limited resources settings at the community level. In line with available data 
and analysing existing guidelines, a practical algorithm for management of hypertension at 
the community level including treatment affordability has been suggested in the present 
work. 
Abstract words count: 215 words 
Main text words count (excluded figures legends, tables and references): 3140 words 
Keywords: Hypertension, prevalence, cost of illness, sub-Saharan Africa, African 
Continental Ancestry Groups. 
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Introduction  
According to the World Health Organization (WHO), hypertension is one of 7 diseases 
composing the entity of “cardiovascular diseases” (CVDs) (1). CVDs account for one third of 
the worldwide global mortality and one tenth of the worldwide global disease burden (2). 
Low- and middle-income countries (LMIC), contribute to 80% of this global CVD burden (2) 
where they cause twice as many deaths as HIV, malaria, and tuberculosis combined, 
becoming  the number-one cause of death in the developing world (3, 4). By its target organ 
damage (TOD) hypertension remains an important cause of coronary heart disease, 
cerebrovascular disease, peripheral artery disease, and heart failure (5). Those latter account 
for more than 70% of  CVD’s morbi-mortality worldwide (1, 3), making hypertension so far 
the major cardiovascular risk factor and major component of the CVD entity. 
In the LMIC of sub-Saharan Africa (SSA), the mortality among patients hospitalized for 
hypertension-related disorders is over 20% (6). Hence, controlling major cardiovascular risk 
factors such as hypertension may reduce the CVD burden (7). But in SSA like in other LMIC, 
one of the major constraints for controlling CVD in general and hypertension in particular, is 
the limitation of resources for health care (7).  
Primary prevention through a population-based, lifestyle-linked programme, as well as cost-
effective methods for detection and management are synergistically linked. Cost-effective 
healthcare interventions to reduce the cardiovascular burden can only be implemented if the 
health services policy environment and financing enable implementation. The control of 
hypertension supposes an early detection. In this context, there are currently no useful 
guidelines to detect and treat hypertension at community level in SSA.  
The guidelines for management of hypertension change constantly as research findings shed 
more insight into the disease mechanisms and as new classes of antihypertensive agents are 
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developed. Since management of hypertension depends on a number of factors including 
demographic and socio-economic realities, what is prescribed in developed countries may not 
be applicable in SSA. Up to now many guidelines have been published but they are scarcely 
implemented in SSA since they don’t suggest any practical management algorithm for health 
professionals in low income countries (8). Additionally, restrained economic conditions in 
the developing world suggest that the greatest gains in controlling hypertension in SSA lie in 
its prevention and awareness of being hypertensive. Attempts should be made to early detect 
hypertensive patients before irreversible organ damage becomes apparent, and to provide 
them with the best possible and affordable non-pharmacological and pharmacological 
treatment. 
This article analyses available data on hypertension complications in SSA and discusses the 
current hypertension management guidelines and ways to improve their implementation in 
SSA. The purpose is to interpret the available facts on the management of hypertension, to 
consider the realities of SSA and to suggest practical algorithms of hypertension detection 
and management at the community level in SSA low- and middle income settings. 
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Methods and the literature search 
A thorough literature search was done on existing global and regional hypertension 
management guidelines.  Country based guidelines were skipped. Additionally, an analysis 
was done on published hospital data about prevalence of hypertension and its complications 
in SSA. In this review, 202 studies reporting hospital data from SSA were retrieved from the 
following databases: MEDLINE through PubMed, MBASE, African Index Medicus and 
WHO Global Cardiovascular InfoBase. Following search terms were used: Sub-Saharan 
Africa /Africa, hypertension/high blood pressure, prevalence, hypertension complications, 
less developed countries / developing countries or nations, hospital/healthcare surveys, 
primary health care, African continental ancestry group, stroke, coronary (heart) diseases, 
heart failure, end-stage renal disease/renal failure and epidemiology. Additional searches 
were done manually using references cited in reviews and original studies and no language 
exclusion was applied. To obtain data close to the current situation, only studies reporting 
data about prevalence and complications published between 1998 and 2008 were included. 
The reported prevalences were extracted as it is (in %), and overall results were expressed as 
medians. The retrieved articles included 167 papers using the current definition of 
hypertension. The reported prevalences (Table 1) were obtained in specialised cardiology 
centres (49 studies), internal medicine departments (21 studies) or in the entire hospital (97 
studies).  
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Results and discussion 
Are international guidelines on management of hypertension applicable to SSA? 
Four main international or regional guidelines for the management of hypertension were 
analyzed. They include [1] the 2003 WHO/ISH Statement on Management of Hypertension 
(9);  [2]  the European guideline, issued by European Society of Hypertension (ESH) and 
European society of cardiology (ESC): the 2007 ESH/ESC guidelines (10) and [3] the United 
States of America (US) guideline, issued by the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure: the 2003 JNC 7 report (11) 
and [4] Recommendations for prevention, diagnosis and management of hypertension and 
cardiovascular risk factors in sub-Saharan Africa (12).  
Besides those main guidelines other documents and reports have been published to help in 
management of hypertension in particular settings, including: [1] the consensus statement of 
the Hypertension in African-Americans working group of the International Society on 
Hypertension in Blacks (13), and [2] the 2002 WHO Cardiovascular Risk Management 
Package in Low- and Medium-Resource Settings (14).  
In sub-Saharan Africa, efforts to establish a guideline for hypertension management have 
been started but so far only one guideline exists since 2003 (12). This guideline has been 
criticized for not considering cost-effectiveness, or cost-savings issues, in the rational choice 
of antihypertensive drugs (15). Moreover, this guideline is limited to the hospital setting and 
is not suitable for the community level. In addition, it is mainly based on blood pressure level 
threshold rather than the total cardiovascular risk and may yield a high number of people to 
treat (16), whereas many SSA countries with limited resources cannot treat everyone with a 
blood pressure (BP) beyond the defined thresholds (BP≥140/90 mmHg) (9, 17). Because of a 
lack of clear risk stratification, it has been poorly implemented and health professionals in 
SSA tried rather to implement the international guidelines or to treat hypertension according 
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to their daily experience (18). This practice led to irrational use of available resources and a 
lack of harmonization in hypertension treatment in SSA region, which can have an impact on  
treatment optimization (19, 20).   
 
Differences in hypertension risk between western countries and SSA countries 
Inhabitants of SSA have higher risk to become hypertensive 
Recognition of the special importance of hypertension in populations of African ancestry 
emerged in the USA in the 1930s (21). By the 1960s surveys have established the two-fold 
greater prevalence of this disorder in Blacks than in Whites (21). In contrast, the relatively 
low prevalence of hypertension in black people living in SSA may mistakenly suggest that 
the risk for hypertension is lower in SSA compared to western countries. Although the 
prevalence of hypertension was lower in SSA than in England and USA, the prevalence of 
hypertension adjusted to the WHO standard population was higher in SSA than in England 
and similar to USA (Table 2). In addition, the analysis of age-specific prevalence data shows 
that the hypertension prevalence is higher at younger ages (up to 45 yrs) in SSA compared to 
western countries. The prevalence in old people is lower in SSA than in western countries. 
The plausible explanation is linked to low accessibility to treatment: by lacking adequate 
treatment people with hypertension died at younger age (around 45-54 years). People with 
hypertension at older age are likely new cases or survivors. The present data also show that 
country prevalence data can be misleading as indicator of the risk for becoming hypertensive.  
 
Differences in risk from hypertension 
The particular context of SSA containing poverty and illiteracy contributes to the low 
awareness, control and treatment rate of hypertension (22). The limited resources devoted 
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toward health care limit the number of health facilities added to the inexistence of health 
insurance scheme (23). In such context, the cases of malignant hypertension and target organ 
damage are frequent (24).  As no official data on risk from hypertension or cardiovascular 
morbidity and mortality exist, data on risk from hypertension in SSA are mainly estimated 
from hospital data.  
Data from inhospital studies show that the most frequent complication reported downward 
are heart failure, renal failure, stroke and coronary heart disease (CHD) (Table 1). The 
reported prevalences were obtained in specialized cardiology centers, internal medicine 
departments or in the whole hospital. Only few studies reported the mean age of the patient 
sample (15 out of 167 hospital studies), and this mean age ranged from 42.5±21.4 years to 
53.8±17.0 years. The total range of age reported in hospital studies was 26-84 years. 
Within 60 studies reporting cardiovascular accidents, only 17 studies reported coronary heart 
disease (CHD) with a rather low prevalence. CHD is relatively uncommon in SSA, probably 
because blacks in SSA have lower serum cholesterol levels and higher high-density 
lipoprotein cholesterol levels (12). Some authors (25) merely link the CHD to mainly 
hypertension in SSA settings, and stress that CHD primary prevention should focus mainly 
on anti-hypertensive measures. 
Heart failure was most frequently reported (74 hospital studies) as a clinical consequence 
attributed to hypertension. Other potential cause of heart failure like rheumatic heart disease 
(24) or myocarditis (presumably linked to infectious diseases like streptococcus and HIV 
infections (26, 27) are frequent in SSA settings. However, the  uncontrolled blood pressure 
remains the major factor for left ventricular hypertrophy (LVH) (28) and heart failure (29, 
30). The same holds for stroke (24, 31, 32)  and renal failure (33-35).  Despite insufficiency 
of statistical data about a relationship between hypertension and End-Stage Renal disease 
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(ESRD) in SSA, current hospital data (Table 1) place ESRD at second position as 
hypertension complication.  
Like in western countries stroke is also in SSA a more common complication of hypertension 
and cause of death than myocardial infarction (36). Stroke cases are presumed to occur at 
home and seldom reach the hospital. Therefore, it is likely that stroke is a more common 
complication than reported by hospital data. This is supported by investigations carried out in 
rural/urban areas; those reported data (32) show a high prevalence of stroke in black Africans 
in SSA, even higher than in western countries (31) and it is suggested that untreated 
hypertension is an important factor (32, 37).  
The current findings, in line with other reports from developing countries (38, 39), show that 
hypertension is emerging as a cardiovascular leading cause of mortality, morbidity and 
disability in adults in many developing nations. They illustrate also the economic 
consequences of hypertension in low- and middle income countries of SSA. In this economic 
context, hypertension complications which occur at much earlier ages in SSA, result in a 
greater number of years of potential life lost. Because of its high prevalence, the treatment of 
hypertension put economic pressure on the SSA community.  
Differences in total cardiovascular risk 
The uncontrolled blood pressure is the main factor for target organ damage, and in SSA 
setting its proportion may be higher than in western countries. Other risk factors, related to 
metabolic syndrome, diabetes and overweight which were considered to be lower in some 
regions of SSA, will increase with urbanization and lifestyle change with modernization (40). 
Despite the lower total cholesterol levels in SSA, the level of blood pressure may bring the 
total cardiovascular risk at the same magnitude as in western countries. In addition, 
hypertension bears the particularity of hitting the active young people, and then affecting the 
SSA economy (41). 
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Different focus in preventive strategies 
The preventive actions concern habits and lifestyle monitoring. Two important low (or no)-
cost preventive measures are first, a reduction in dietary salt intake (13), and second, a greater 
awareness of the implications of obesity (42). There is good evidence that a reduction in salt 
intake reduces blood pressure and that black people are more sensitive than white people in 
this regard (43). Other measures as increased physical exercise (44), decreased obesity, 
cessation of smoking and limited alcohol consumption (45) are all as important in black 
subjects as in whites in prevention and control of hypertension. As hypertension is occurring 
at younger age in SSA than in western countries, regular check of blood pressure for all (also 
young) adult people should be promoted. 
Diet control in SSA remains a great challenge. The diet is highly linked to the population 
culture, to the food conservation, cooking, and other existing infrastructures. Salt reduction  
may be difficult in populations using it for food conservation. The implementation of 
controlled diets like promoted in Dietary Approaches to Stop Hypertension (DASH) (46, 47), 
may be difficult in SSA settings because those measures require change in preparation, 
conservation and other infrastructures and resources not available in SSA.  Since the 
conservation of food in SSA can be difficult, fresh food should be promoted. 
 
Different focus in therapeutic strategies 
Beyond prevention measures (48-50), the management of hypertension includes also non-
pharmacological (19, 51) and pharmacological treatment (52) and both bear specificities in 
SSA. Although the content of non-pharmacological treatment mainly based on lifestyle 
change and promoted by a patient education package remains similar in western countries 
and SSA, a difference in outcome can be expected from the high illiteracy rate in SSA. This 
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may require different educational methods. Moreover, the population cultures and the real 
way of living (activities, historic habits like salt intake, etc) must be taken into account. 
Furthermore, since resources for managing hypertension are limited, it is important that 
interventions are guided by cost-effectiveness for low- and middle-income countries (4). 
Hence, it is vital to use the scarce resources with maximum efficiency and guidelines should 
include drug affordability as main management component.  
Hypertension management in public health perspective 
Setting up a suitable guideline for the management of hypertension in SSA taking into 
account the local situation remains the great challenge (8). To author’s knowledge, this is the 
first paper to suggest an algorithm for early detection and management of hypertension at the 
community level in low-and middle income countries.  
Beyond protocols suggested in the 2002 WHO Cardiovascular Risk Management Package in 
Low- and Medium-Resource Settings (14), we propose a set of algorithms (Figure 1-4) for 
detecting and managing hypertension in SSA at the community level. Since the SSA region 
has its own disparities between countries, proposed algorithms offer the flexibility to be 
adapted to the countries’ situation. As at the community level it’s not feasible to have all 
parameters used in scoring total cardiovascular risk (such as total cholesterol), the proposed 
algorithm for the community level mainly relies on the blood pressure level which is the main 
component in calculating the total cardiovascular risk (53). In addition, the algorithm largely 
takes into account drug affordability. This algorithm is not suitable at hospital level, where 
other guidelines based on risk prediction charts (10, 54) may apply. The proposed algorithm 
for community level is based on [1] a two level management: at health advisor/worker and at 
health center; [2] detection and prevention of hypertension and nonpharmacological treatment 
at both levels, [3] prescription of a limited number (two) of low dose affordable 
antihypertensive drugs limited to the health center, [4] a management based on blood 
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pressure level and presence of other cardiovascular risk factors, and [5] referral of high risk 
patients to the hospital. 
Prerequisites are first, to provide at the community health advisor and health center level the 
blood pressure devices and second, to provide the core drugs (hydrochrolothiazide or other 
thiazides diuretics, and prazosin and/or reserpine) at the health center level. The good storage 
of medicines at the health centre, the training of nurses and organization of population 
sensitization programs are also pre-requisite to implement the suggested algorithm. 
Implementation of the proposed algorithm may implicate new investment and a 
reorganization of the health sector in some places.  
As recommended by World Bank publication “Better Health for Africa” (55), at the 
community level (village), in a majority of SSA countries there are elected persons called 
“village health workers”. Even if those delegates have no formal medical training, they are 
generally the most educated of the population and they can be trained in taking just blood 
pressure at their offices where they hold regular meetings with the population and give advice 
on non pharmacological treatment and hypertension prevention. 
Health centers have nurses and other health professionals, but rarely a medical doctor (56). 
The use of pre-established flowcharts for the management of hypertension at the community 
level is likely to increase patients’ accessibility to health care. Sticks for detection of 
proteinuria and urine glucose are frequently available. If an electrocardiogram (ECG) can be 
done, the nurse must be trained to make a proper ECG recording, and to calculate the Cornell 
product for left ventricular hypertrophy detection (57). Because of its high specificity and 
better sensitivity the Cornell product is preferred over other indexes such as Sokolow-
Lyon voltage (58) and the 12 lead-QRS product 
Low dose thiazide diuretics proposed in the present algorithm, are still proposed as backbone 
of the hypertension treatment in general (59-62) since they have a good affordability in most 
(57) . 
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SSA countries (63). In addition, at this low dose, dangerous side effects like hypokalemia 
(which can induce arrhythmias) are less expected.  
Although alpha-blockers like prazosin may be an alternative to thiazides and cheaper, they 
have the disadvantage of a three times daily intake, which can reduce treatment adherence. 
Other side effects of alpha-blockers like the "first-dose effect" (inducing orthostatic 
hypotension) can be limited by starting the treatment with a low dose and increasing the dose 
slowly. For these reasons, alpha-blockers may not be first-line drugs at the health center 
level. Reserpine or rauwolfia extracts offer the advantage of low cost and a once-daily 
administration. Side effects like nasal congestion or depression are less frequent provided the 
dosage of reserpine does not exceed 0.1 mg once daily. These drugs are proposed in third line 
at the health center setting. They could be chosen in second line when compliance with 
prazosin is bad or when side effects occur. 
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Conclusions  
Hypertension is emerging as a cardiovascular leading cause of mortality, morbidity and 
disability in adults in many developing nations. In contrast with western countries there’s 
higher risk for hypertension in SSA and the higher risk is particularly found at the young age 
(<45 yr). Hypertension complications in SSA are dominated by heart failure. To prevent 
complications efforts should be made in early detection and management at the community 
level. International guidelines for hypertension management cannot apply to SSA settings, 
where limited resources and patients’ affordability do not allow access to advocated 
treatment. A practical algorithm for management of hypertension at the community level 
including treatment affordability has been proposed in the present work. 
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Tables 
Table 1. Summary of hospital reported data  
 
Notes:  [1] “n” means number of studies; [2] most of cases are probably transferred in other 
specific unities like dialyses or intensive care, underestimating the frequency in cardiology 
based or internal medicine centers;  [3] Median of the studies reporting the mean age of the 
patients’ sample (15 out of 167). 
 
 
 
Source of Data Age in 
years: 
median 
(range) [3] 
 
Reported prevalence of complications in  % (and range) 
Heart failure 
Coronary Heart 
Disease – CHD 
(when reported 
alone) 
Stroke 
(when reported alone) 
End Stage Renal 
Disease [2] 
 
number 
of 
studies 
n 
[1] 
Median 
(range) 
 
 
n 
Median 
(range ) 
n 
Median 
(range ) 
n 
Median 
(range ) 
Specialised 
cardiology centre 
49 
47.1 
(26 – 84) 
28 
61.8 
(29.0 – 
79.2) 
7 
13.9 
(2.4 – 35.0) 
8 
19.4 
(10.1 – 45.8) 
7 
14.4 
(1.0 – 39.3) 
Internal medicine 
department 
21 
56.2 
(45 – 68) 
7 
29.0 
(11.3 – 37.9 
8 
4.1 
(1.9 – 8.9) 
8 
9.8 
(2.0 – 20.4) 
4 
10.3 
(0.7 – 27.8) 
Entire hospital 97 
50.3 
(40 – 77) 
25 
13.7 
(0.7 – 32.3 
16 
0.6 
(0.3 – 7.2) 
18 
1.2 
(0.6 – 11.0) 
12 
3.8 
(0.6 – 15.9) 
Total 167 
54.5 
(26 – 84) 
60 
16.1 
(0.7 – 79.2) 
31 
0.9 
(0.3 – 35.0) 
34 
2.8 
(0.6 – 45.8) 
25 
4.1 
(0.6 – 39.3) 
Ratio’s versus stroke prevalences, from 
studies reporting both complications.  
(read as “x times frequent vs stroke”) 
3.60±3.77  
(23 studies) 
0.78±0.63  
(21 studies) 
1 
0.45±0.38  
(12 studies) 
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Table 2. Comparison between SSA pooled data and developed countries surveys. 
 
 Crude hypertension prevalence in % (number of diagnosed hypertensive people/sample size) 
Statistical comparison test 
p-value 
Age-range[a] [1]SSA(64) [2] England(65) [3] USA(66) Within all 
SSA 
vs 
England 
SSA 
vs 
USA 
15-34 8.3 (2,454/29,725) 
4.2 
(33,461/798,390) 
6.0 
(178/2,971) 
<0.001 <0.001* <0.001* 
35-44 17.1 (1,993/11,653) 
12.3 
(60,128/487,692) 
16.0 
(135/846) 
<0.001 <0.001* NS 
45-54 28.8 (2,395/8,317) 
26.3 
(102,484/389,053) 
31.0 
(242/781) 
<0.001 <0.001* NS 
55-64 44.0 (2,969/6,747) 
45.8 
(162,533/355,094) 
48.0 
(312/650) 
0.045 0.004 NS 
≥65 60.1 (1,511/2,514) 
61.2 
(333,947/545,786) 
71.4 
(849/1,189) <0.001 NS <0.001 
Overall  16.2 (11,322/58,956) 
26.9 
(692,553/2,576,015) 
28.4 
(1,716/6,437) <0.001 <0.001 <0.001 
Prevalence 
standardized 
for WHO 
standard 
population [4] 
23.3 18.4 21.6 <0.001 <0.001* NS 
[a] Age range for USA prevalence starts from 18 years, for England are from 16 years and 
for SSA are from 15 years; [1] Results from a compilation of population-based studies (64); 
[2] Results from the Health Improvement Network (THIN) database & Health Survey for 
England (HSE)(65); [3] NHANES III continuous(66); [4] WHO standard population adjusted 
prevalence; NS: Not statistically significant *SSA is statistically higher.  
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Table 3. The present paper summary 
What is known on the topic What this paper adds 
• Hypertension is emerging in many 
developing nations as a leading cause of 
cardiovascular mortality, morbidity and 
disability in adults.  
• Many international and regional 
guidelines for hypertension management 
have been published but few of them 
propose a clear algorithm for 
management at the community level in 
limited resources settings.  
 
• In sub-Saharan Africa (SSA), 
hypertension has specificities like 
occurring in young and active adults, 
resulting in severe complications and 
taking place in limited resource settings 
where individual access to treatment 
(affordability) is very limited. 
• The reported hospital complications are 
dominated by heart failure. 
• A proposal of a practical algorithm for 
early detection and management of 
hypertension at the community level 
including treatment affordability, in line 
with available data and analysis of 
existing guidelines. 
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Figures legends/captions 
Figure 1. Hypertension management strategy at the community level : At least, where a 
health advisor/worker is available. 
Legends: 
NPT: Non-pharmacological treatment; SBP: Systolic blood pressure; DBP: Diastolic blood 
pressure 
Notes: 
(*) Symptoms to ask (Yes means the person answers yes at least to one of following 
questions): 
- Shortness of breath on small exercise (like climbing a small distance, walking, etc) 
- Both feet swollen. 
 
(**)Non pharmacological treatment (NPT) includes: 
- Stop smoking (keep in mind all kind of tobacco use) 
- Overweight reduction and Recommendation of a regular physical activity 
- Dietetic measures: (Salt reduction, promote fresh fruits and vegetables intake, fatty food 
limitation, minimizing alcohol intake) 
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Figure 2. Hypertension management algorithm at the health centre: the first step 
Legends: 
ECG= Electrocardiography;  NPT: Non-pharmacological treatment; CVR: Cardiovascular 
risk factors; SBP: Systolic blood pressure; DBP: Diastolic blood pressure 
Notes: 
[1] Minimal equipment: urine sticks for protein and glucose and preferentially a standard 
Electrocardiography.  
[2] At CVR evaluation “Yes” means at least one cardiovascular risk factor is present; the 
cardiovascular factors to detect are: 
       (a) Proteinuria (using dipsticks) 
       (b) Glucosuria (using dipsticks). If positive follow also instructions for diabetes. 
       (c) The left ventricular hypertrophy(LVH) on ECG; defined by a Cornell product 
parameter  
            (positive if >2440 mm*msec). The parameter is calculated as follows: 
- Cornell product = (RaVL + SV3) × QRS duration (meaning the product of 
QRS duration with the sum of the R wave in lead “aVL” and the “S” wave in 
lead “V3”). The RaVL, SV3, QRS and V3 being ECG waves. 
- To measure QRS duration on ECG, recorded at a speed of 25 mm/sec:  
- Principles:  
 1mV=10mm in the vertical direction.  
 Each small 1-mm square represents 0.04sec (40msec) in time and 0.1mV in 
voltage. 
 QRS duration: counting 1-mm square cell of the ECG, paper corresponding 
to the beginning and the end of QRS complex (horizontally), and then multiply 
the number by 40 msec.  
- R and S wave voltage are obtained by counting the number of 1-mm square 
cell (vertically) corresponding to the wave height (amplitude).  
[3] The patient’s affordability is evaluated based on socio-economic data provided in his 
medical record (file) and on patient interview.  
[4] The (*) and (**) signs refer to the same legend as in figure 1. 
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Figure 3. Drug treatment algorithm at the health centre in hypertensives with low 
affordability (following the first step of management showed in Figure 2). 
Legends: 
HCTZ= Hydrochlorothiazide  
Notes: 
The patient’s treatment adherence is evaluated by patient and near neighbourhood 
interviews.  The goal to be achieved are stipulated in figure 2. 
 
 
Figure 4. Drug treatment algorithm at the health centre in hypertensives with high 
affordability (following the first step of management showed in Figure 2). 
Notes: 
The patient’s treatment adherence is evaluated by patient and near neighbourhood 
interviews.  The goal to be achieved are stipulated in figure 2. 
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Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
   
 
 
 
 
 
 
Measurements of  
blood pressure (BP) 
in all adults 
 (i.e. ≥ 25 years),  
at least once year.  
If SBP≥ 140mmHg  
and/or  
DBP ≥90mmHg 
 
 
Check again 3 times 
at minimal 1 minute 
interval 
 
If SBP<140mmHg  
and  
DBP <90mmHg 
 
 
If SBP: 140-159mmHg 
and/or  
DBP: 90-99mmHg 
 
 
If SBP>180mmHg 
and/or  
DBP >110mmHg 
 
 
If SBP: 160-179mmHg 
and/or  
DBP: 100-109mmHg 
 
 
12 months’ 
evaluation 
 
NPT (**) 
NPT (**) 
 
Refer to a health center 
6 months’ 
evaluation 
3 months’ 
evaluation 
If SBP≥140mmHg 
and/or  
DBP≥90mmHg 
 
If SBP<140mmHg  
and  
DBP<90mmHg 
 
Ask for symptoms (*) 
If SBP≥ 140mmHg 
and/or  
DBP ≥90mmHg 
No 
Yes 
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Figure 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Refer to hospital  
If SBP: 180-200mmHg  
and/or  
DBP: 110-120mmHg 
If SBP: 160-179mmHg 
and/or  
DBP: 100-109mmHg 
Measure blood 
pressure (BP) in 
all adults (>25 
years), even in 
referred patients. 
 
If SBP>200mmHg 
and/or  
DBP >120mmHg 
 
 
If SBP<160mmHg 
or  
DBP <100mmHg 
CVR  
No 
No 
Yes 
Yes 
Refer to 
community level 
NPT (**) 
High 
affordability 
No other CVR 
(The treatment goal is 
SBP<160mmHg and  
DBP <95mmHg)  
NPT  
+  
Drugs 
 
 
(For drug 
treatment, 
evaluate 
affordability 
and follow 
the specific 
algorithm) 
 
Yes 
Existence of other CVR 
(The treatment goal is 
SBP<140mmHg and 
DBP <90mmHg)  
Ask for 
symptoms  (*) 
If SBP≥ 140mmHg 
or DBP ≥90mmHg 
If SBP<140mmHg  
and  
DBP <90mmHg 
 
 
Yes 
No 
CVR  
CVR  
6 months’ 
evaluation  
Follow the 
« TREATMENT ALGORITHM: 
LOW AFFORDABILITY » 
Follow the 
« TREATMENT ALGORITHM: 
HIGH AFFORDABILITY » 
Low  
Affordability 
6 months’ 
evaluation  
NPT (**) 
SBP>160mmHg 
and/or  
DBP >95mmHg 
SBP<160mmHg  
and 
 DBP <95mmHg 
No NPT (**) 6 months’ evaluation  
SBP>140mmHg  
and/or  
DBP >90mmHg 
SBP<140mmHg  
and 
DBP <90mmHg 
SBP>140mmHg 
and/or  
DBP >90mmHg 
SBP<140mmHg  
and  
DBP <90mmHg 
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Figure 3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
HCTZ 12.5 mg/day + Prazosin 3x1mg/day 
(start by low dose 3x0.5mg/day, and increase it 
on 3 days, until the daily dose) 
Starting by small doses of 
thiazides duretics 
   
  
6-weeks’ 
evaluation 
HCTZ 12.5 mg/day + Prazosin 3x2mg/day 
(start by low doses 3x1.5mg/day, and 
increase it on 3 days, until the daily dose) 
Goal achieved 
Yes 
If there was a good adherence  If there was a bad compliance , 
provide the information to improve it. 
Ask about treatment 
adherence 
No 
Same treatment and check every 6 months 
6-weeks’ evaluation:  
Bad tolerance AND/OR Gaol not 
achieved 
Refer the patient to the hospital 
 
If goal achieved, continue the same 
treatment and control every 3 
months. 
Replace the Prazosin by the Reserpine low dose 
Eg. 0.05mg/day and if good tolerability increase up to 0.1mg/day 
 
6-weeks’ evaluation:  
CHECK TOLERABILITY  
Same treatment and check 
every 6 months 
No 
Goal achieved 
Ask about treatment 
adherence 
Yes 
Goal not achieved 
If there was a good adherence  If there was a bad adherence, 
provide the information to improve it.  
6-weeks’ evaluation: 
CHECK TOLERABILITY  
Same treatment and check every 6 months 
No 
Goal achieved 
Ask about treatment 
adherence 
Yes 
Goal not achieved 
If there was a good adherence  If there was a bad adherence, 
provide the information to improve it.  
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Figure 4.  
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hospital If there was a good compliance  
If there was a bad adherence, provide 
the information to improve it.  
Ask about treatment 
adherence 
Starting by small doses of 
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